| 前收盘价格 | 3.18 |
| 收盘价格 | 3.20 |
| 成交量 | 15,165 |
| 平均成交量 (3个月) | 24,600 |
| 市值 | 28,779,618 |
| 价格/销量 (P/S) | 17.75 |
| 52周波幅 | |
| 利润日期 | 16 Sep 2025 - 22 Sep 2025 |
| 营业利益率 (TTM) | -1,264.64% |
| 稀释每股收益 (EPS TTM) | -3.63 |
| 季度收入增长率 (YOY) | 501.40% |
| 总债务/股东权益 (D/E MRQ) | 6,456.94% |
| 流动比率 (MRQ) | 4.81 |
| 营业现金流 (OCF TTM) | -17.31 M |
| 杠杆自由现金流 (LFCF TTM) | -11.34 M |
| 资产报酬率 (ROA TTM) | -36.57% |
| 股东权益报酬率 (ROE TTM) | -1,833.59% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Pluri Inc. | 混合的 | - |
AIStockmoo 评分
0.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.17 |
|
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company’s technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 43.87% |
| 机构持股比例 | 19.40% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Values First Advisors, Inc. | 30 Sep 2025 | 11,907 |
| Eversource Wealth Advisors, Llc | 30 Sep 2025 | 2,000 |
| Wells Fargo & Company/Mn | 30 Sep 2025 | 185 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 30 Sep 2025 | 136 |
| Royal Bank Of Canada | 30 Sep 2025 | 125 |
| Td Waterhouse Canada Inc. | 30 Sep 2025 | 93 |
| Quent Capital, Llc | 30 Sep 2025 | 57 |
| Osaic Holdings, Inc. | 30 Sep 2025 | 50 |
| Sbi Securities Co., Ltd. | 30 Sep 2025 | 50 |
| Huntington National Bank | 30 Sep 2025 | 38 |
| Winch Advisory Services, Llc | 30 Sep 2025 | 26 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合